Vorinostat clinical trials
Also written Zolinza, suberoylanilide hydroxamic acid, MSK-390 and MK-0683.
How each study uses Vorinostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Vorinostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 6 Oct 2006 · ZOLINZA · NDA 021991 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
233 studies that test it; most in 2009 (34)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 27 |
| 2006 | 22 |
| 2007 | 17 |
| 2008 | 25 |
| 2009 | 34 |
| 2010 | 23 |
| 2011 | 12 |
| 2012 | 14 |
| 2013 | 8 |
| 2014 | 7 |
| 2015 | 8 |
| 2016 | 5 |
| 2017 | 9 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 28 · Other 207
National Cancer Institute (NCI) (57) · Merck Sharp & Dohme LLC (26) · M.D. Anderson Cancer Center (16) · University of Washington (6) · City of Hope Medical Center (5) · Fred Hutchinson Cancer Center (5) · H. Lee Moffitt Cancer Center and Research Institute (4) · Masonic Cancer Center, University of Minnesota (4)
Often tested with
Tested in the same studies.
Bortezomib (22) · Dexamethasone (8) · Decitabine (8) · Gemcitabine (8) · Lenalidomide (7) · Cytarabine (6) · Doxorubicin (6) · Rituximab (5)
Related medicines
As reviewed, each with the page that says it.
- One of HDAC inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 9
Studies that test Vorinostat.
- Dec 2026Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate CancerPhase 2 · Fred Hutchinson Cancer Center
- Dec 2026Vorinostat in Treating Patients With Metastatic Melanoma of the EyePhase 2 · National Cancer Institute (NCI)
- Dec 2026Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaPhase 1/2 · National Cancer Institute (NCI)
- Dec 2026Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett SyndromePhase 1 · Unravel Biosciences, Inc.
- Dec 2026An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins SyndromePhase 1 · Unravel Biosciences, Inc.
- Dec 2026Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS MalignanciesPhase 1 · New York Medical College
- Jan 2027A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]Early Phase 1 · University of Minnesota
- Jun 2027A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaPhase 1/2 · Hackensack Meridian Health
- Jul 2027Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell TransplantationPhase 1 · Johns Hopkins All Children's Hospital
Studies
Open first, then newest update. How each study uses Vorinostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 235
- An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With UstekinumabRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT03167437Written as Vorinostat
- Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) PopulationRecruitingPhase 2Sung Won ChoiNCT06995521Written as Vorinostat
- Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett SyndromeRecruitingPhase 1Unravel Biosciences, Inc.NCT07150013Written as Vorinostat (SAHA)
- An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins SyndromeRecruitingPhase 1Unravel Biosciences, Inc.NCT07150026Written as Vorinostat (SAHA)
- NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + DinutuximabNot yet recruitingPhase 2New Approaches to Neuroblastoma Therapy ConsortiumNCT07261241Written as Vorinostat
- Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate CancerRecruitingPhase 2Fred Hutchinson Cancer CenterNCT06145633Written as Vorinostat
- A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]RecruitingEarly Phase 1University of MinnesotaNCT06693284Written as mirdametinib and vorinostat
- Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS MalignanciesRecruitingPhase 1New York Medical CollegeNCT04308330Written as Vorinostat
- Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT00972478Written as Vorinostat
- Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell LymphomaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT00336063Written as Vorinostat
- Vorinostat in Treating Patients With Metastatic Melanoma of the EyeActive, not recruitingPhase 2National Cancer Institute (NCI)NCT01587352Written as Vorinostat
- Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT00392353Written as Vorinostat
- Vorinostat and Temozolomide in Treating Patients With Malignant GliomasActive, not recruitingPhase 1National Cancer Institute (NCI)NCT00268385Written as Vorinostat
- Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.Active, not recruitingPhase 1City of Hope Medical CenterNCT03150329Written as Vorinostat
- Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast CancerCompletedPhase 1City of Hope Medical CenterNCT01084057Written as vorinostat
- Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT02638090Written as Vorinostat
- Vorinostat in Combination With Vinorelbine in Patients With Advanced CancerTerminatedPhase 1Institut Claudius RegaudNCT00801151Written as Zolinza (vorinostat), vinorelbine
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaActive, not recruitingPhase 1/2Hackensack Meridian HealthNCT01297764Written as Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
- Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell TransplantationActive, not recruitingPhase 1Johns Hopkins All Children's HospitalNCT03843528Written as Vorinostat
- Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) IActive, not recruitingPhase 1/2St. Jude Children's Research HospitalNCT02553460Written as Vorinostat
See all 235 studies that test Vorinostat →
Given beside what is tested · 25 — Vorinostat is usual care or a partner of the new treatment
- TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIRecruitingPhase 1/2Tanja Andrea GruberNCT05848687Written as Vorinostat
- Pediatric Precision Laboratory Advanced Neuroblastoma TherapyRecruitingPhase 2Giselle ShollerNCT02559778Written as vorinostat
- Venetoclax to Augment Epigenetic Modification and ChemotherapyRecruitingPhase 1Medical College of WisconsinNCT05317403Written as Vorinostat
- Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT01522976Written as Vorinostat
- High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid TumorsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01281176Written as Vorinostat
- The DART DELIVER-02 StudySuspendedPhase 1University of North Carolina, Chapel HillNCT07217379Written as Vorinostat
- Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell TransplantCompletedPhase 1M.D. Anderson Cancer CenterNCT03259503Written as Vorinostat
- Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced CancerActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT01087554Written as Vorinostat
- MIBG With Dinutuximab +/- VorinostatCompletedPhase 1New Approaches to Neuroblastoma Therapy ConsortiumNCT03332667Written as Vorinostat
- Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase InhibitorsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT03382834Written as Vorinostat
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524Written as Vorinostat
- Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV ViremiaWithdrawnPhase 1Masonic Cancer Center, University of MinnesotaNCT05700630Written as Vorinostat
- Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade GliomaCompletedPhase 2/3National Cancer Institute (NCI)NCT01236560Written as Vorinostat
- Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell LymphomasCompletedPhase 1/2National Cancer Institute (NCI)NCT01193842Written as Vorinostat
- MLN9708 and Vorinostat in Patients With Advanced p53 Mutant MalignanciesCompletedPhase 1M.D. Anderson Cancer CenterNCT02042989Written as Vorinostat
- Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected PersonsCompletedPhase 1University of North Carolina, Chapel HillNCT03803605Written as Vorinostat (VOR)
- Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or LymphomaCompletedPhase 1Fox Chase Cancer CenterNCT01169532Written as vorinostat
- Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV InfectionTerminatedPhase 1AIDS Malignancy ConsortiumNCT01249443Written as vorinostat
- Reversing Therapy Resistance With Epigenetic-Immune ModificationTerminatedPhase 2University of California, San FranciscoNCT02395627Written as Vorinostat
- Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedPhase 2M.D. Anderson Cancer CenterNCT00948064Written as Vorinostat
Showing 20 of 25.
As the comparator · 3 — what is tested is compared with Vorinostat
- Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis FungoidesWithdrawnPhase 2Virogen Biotechnology Inc.NCT02943642Written as Vorinostat
- Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCLCompletedPhase 3Kyowa Kirin, Inc.NCT01728805Written as Vorinostat
- SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis FungoidesTerminatedPhase 2miRagen Therapeutics, Inc.NCT03713320Written as Vorinostat
Codes
What other systems call Vorinostat · ClinicalTrials.gg INT006704
- MeSH (NLM) D000077337VorinostatConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 58IFB293JIVORINOSTATConfirmed FDA, NLM, Wikidata
- RxNorm 194337Confirmed FDA, Wikidata
- Wikidata Q905901vorinostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1796VorinostatOne source FDA
- DrugBank DB02546One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077337 | Vorinostat | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 58IFB293JI | VORINOSTAT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 194337 | — | Confirmed FDA, Wikidata |
| Wikidata | Q905901 | vorinostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1796 | Vorinostat | One source FDA |
| DrugBank | DB02546 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.